IO Biotech to Present at Upcoming Investor Conferences, Highlighting Cylembio Therapeutic Cancer Vaccine Candidate

IO Biotech announced participation in upcoming investor conferences, including Morgan Stanley's 23rd Annual Global Healthcare Conference and H.C. Wainwright's 27th Annual Global Investment Conference. The company's senior management team will provide a corporate update and participate in one-on-one meetings. The webcast replay for the fireside chat and presentation will be available on the company's website. IO Biotech is developing an investigational cancer vaccine candidate, Cylembio, in Phase 3 and 2 clinical trials.

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, has announced its participation in two upcoming investor conferences in New York. The company will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 7:45 am ET, featuring a fireside chat with CEO Mai-Britt Zocca, CFO Amy Sullivan, and CMO Qasim Ahmad. Additionally, CEO Mai-Britt Zocca will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 8:00 am ET. Webcasts of both presentations will be available in the Investors section of IO Biotech's website for 90 days following the events.

IO Biotech's lead cancer vaccine candidate, Cylembio®, is currently undergoing pivotal Phase 3 and Phase 2 clinical trials. The Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating Cylembio in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), versus pembrolizumab alone in patients with advanced melanoma, is expected to report topline results in the third quarter of 2025. The company is also conducting a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating Cylembio in combination with pembrolizumab as first-line treatment in patients with advanced solid tumors and another Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating Cylembio as neo-adjuvant/adjuvant treatment of patients with solid tumors. Enrollment in all trials has been completed.

The company's participation in these investor conferences provides an opportunity for investors to gain insights into IO Biotech's clinical progress and strategic direction. The fireside chat and presentation will feature updates on the company's clinical trials, pipeline candidates, and financial position. IO Biotech's CEO, Mai-Britt Zocca, PhD, will lead the discussions, providing valuable insights into the company's vision and plans for the future.

Investors and financial professionals are encouraged to tune in to the webcasts of these events to stay informed about IO Biotech's advancements in the field of cancer immunotherapy.

References:
[1] https://www.globenewswire.com/news-release/2025/09/04/3144481/0/en/IO-Biotech-Announces-Participation-in-Upcoming-Investor-Conferences.html
[2] https://www.stocktitan.net/news/IOBT/io-biotech-announces-participation-in-upcoming-investor-8m2msv58fjrl.html